The U.S. Food and Drug Administration has approved Eli Lilly's GLP-1 pill, Foundayo, for obesity treatment, marking a significant milestone for the Indianapolis-based pharmaceutical company and setting up a new phase of rivalry with Novo Nordisk in the weight-loss drug market [1]. Foundayo, a once-daily pill, will begin shipping from LillyDirect on Monday and will be available at pharmacies and telehealth platforms shortly after, offering increased accessibility for patients [1]. Pricing details indicate that individuals with insurance coverage could pay $25 a month with a coupon from Lilly, while out-of-pocket costs range from $149 to $349 depending on the dose [1].
The FDA approval follows a speedy review process, with Foundayo launching only about three months after Novo Nordisk's Wegovy pill, further intensifying competition between the two companies in the GLP-1 drug market [1]. Eli Lilly CEO Dave Ricks emphasized the pill's accessibility and ease of use, stating, "Here is an option that's not more effective ... but it's more accessible, it's easier to fit into your daily routine" [1]. Foundayo is based on the molecule orforglipron, licensed from Japanese drugmaker Chugai in 2018 for $50 million upfront for global rights [1].
Despite its accessibility, questions remain about Foundayo's market potential, as it does not produce as much weight loss as Lilly's best-selling injection, Zepbound, which millions already use weekly [1]. Analyst estimates from FactSet project Foundayo sales to reach $14.79 billion by 2030, compared to $24.68 billion for Zepbound and $44.87 billion for Mounjaro, which is marketed for diabetes in the U.S. and both obesity and diabetes internationally [1]. Ricks noted that injections have not been as much of a barrier to uptake as initially believed, but he sees Foundayo as an attractive option for those preferring a pill or seeking a lower price than injectables, and as a maintenance therapy for those who have achieved their goal weight with injections [1].
Foundayo's small molecule structure, unlike the peptide-based Zepbound and Wegovy, allows for easier manufacturing and scalability, enabling global launch without the cold-chain constraints associated with injectables [1]. Ricks highlighted that this could limit the emergence of generic versions, as seen with Wegovy in markets like India, and facilitate worldwide marketing of Foundayo [1].
CONCLUSION
Eli Lilly's FDA approval for Foundayo marks a pivotal moment in the weight-loss drug market, offering a more accessible oral option and intensifying competition with Novo Nordisk. While analyst projections suggest substantial sales growth, Foundayo's efficacy compared to injectables and its global scalability are key factors shaping its market impact. The launch is expected to drive high market activity and broaden patient access to obesity treatments.